Potent aldose reductase inhibitor. Improves the cytotoxicity of anticancer reagents such as cisplatin
(Cat.No. 2251) and doxorubicin
(Cat.No. 2252) in HeLa cervical carcinoma cells through an increase in ERK activity.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases.
Kyoung et al.
Anti-cancer Drugs, 2002;13:859
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate and its congeners.
Mylari et al.
The citations listed below are publications that use Tocris products. Selected citations for EBPC include:
Showing Results 1 - 2 of 2